MRC-ECOG UKALLXII/EC2993: outcome after allogeneic hematopoietic stem cell transplantation (HSCT) in Ph−patients who had donors versus those who did not have donors.
| . | No. . | 5-y overall survival, % . | 5-y relapse rates, % . | 2-y nonrelapse mortality, % . |
|---|---|---|---|---|
| * High-risk is defined as age ≥ 35 years, WBC > 30,000/μL for patients with B-cell disease or WBC > 100,000/μL for patients with T-cell disease, or time to attain CR > 4 weeks. | ||||
| High-risk* | 401 | |||
| Donor | 171 | 40 | 39 | 39 |
| No donor | 230 | 36 | 62 | 12 |
| Standard-risk | 512 | |||
| Donor | 218 | 63 | 27 | 20 |
| No donor | 294 | 51 | 50 | 7 |
| . | No. . | 5-y overall survival, % . | 5-y relapse rates, % . | 2-y nonrelapse mortality, % . |
|---|---|---|---|---|
| * High-risk is defined as age ≥ 35 years, WBC > 30,000/μL for patients with B-cell disease or WBC > 100,000/μL for patients with T-cell disease, or time to attain CR > 4 weeks. | ||||
| High-risk* | 401 | |||
| Donor | 171 | 40 | 39 | 39 |
| No donor | 230 | 36 | 62 | 12 |
| Standard-risk | 512 | |||
| Donor | 218 | 63 | 27 | 20 |
| No donor | 294 | 51 | 50 | 7 |